255 related articles for article (PubMed ID: 28677271)
1. Telomerase reverse transcriptase germline mutations and hepatocellular carcinoma in patients with nonalcoholic fatty liver disease.
Donati B; Pietrelli A; Pingitore P; Dongiovanni P; Caddeo A; Walker L; Baselli G; Pelusi S; Rosso C; Vanni E; Daly A; Mancina RM; Grieco A; Miele L; Grimaudo S; Craxi A; Petta S; De Luca L; Maier S; Soardo G; Bugianesi E; Colli F; Romagnoli R; Anstee QM; Reeves HL; Fracanzani AL; Fargion S; Romeo S; Valenti L
Cancer Med; 2017 Aug; 6(8):1930-1940. PubMed ID: 28677271
[TBL] [Abstract][Full Text] [Related]
2. Telomere Dysfunction in Nonalcoholic Fatty Liver Disease and Cryptogenic Cirrhosis.
Laish I; Mannasse-Green B; Hadary R; Biron-Shental T; Konikoff FM; Amiel A; Kitay-Cohen Y
Cytogenet Genome Res; 2016; 150(2):93-99. PubMed ID: 28006764
[TBL] [Abstract][Full Text] [Related]
3. Telomere biology and telomerase mutations in cirrhotic patients with hepatocellular carcinoma.
Donaires FS; Scatena NF; Alves-Paiva RM; Podlevsky JD; Logeswaran D; Santana BA; Teixeira AC; Chen JJ; Calado RT; Martinelli ALC
PLoS One; 2017; 12(8):e0183287. PubMed ID: 28813500
[TBL] [Abstract][Full Text] [Related]
4. Telomeres, NAFLD and Chronic Liver Disease.
Donati B; Valenti L
Int J Mol Sci; 2016 Mar; 17(3):383. PubMed ID: 26999107
[TBL] [Abstract][Full Text] [Related]
5. Hepatocellular carcinoma in nonalcoholic fatty liver: role of environmental and genetic factors.
Dongiovanni P; Romeo S; Valenti L
World J Gastroenterol; 2014 Sep; 20(36):12945-55. PubMed ID: 25278690
[TBL] [Abstract][Full Text] [Related]
6. Carriage of the PNPLA3 rs738409 C >G polymorphism confers an increased risk of non-alcoholic fatty liver disease associated hepatocellular carcinoma.
Liu YL; Patman GL; Leathart JB; Piguet AC; Burt AD; Dufour JF; Day CP; Daly AK; Reeves HL; Anstee QM
J Hepatol; 2014 Jul; 61(1):75-81. PubMed ID: 24607626
[TBL] [Abstract][Full Text] [Related]
7. Telomerase activity, telomere length and human telomerase reverse transcriptase expression in hepatocellular carcinoma is independent of hepatitis virus status.
Saini N; Srinivasan R; Chawla Y; Sharma S; Chakraborti A; Rajwanshi A
Liver Int; 2009 Sep; 29(8):1162-70. PubMed ID: 19627485
[TBL] [Abstract][Full Text] [Related]
8. TERT promoter mutations and chromosome 8p loss are characteristic of nonalcoholic fatty liver disease-related hepatocellular carcinoma.
Ki Kim S; Ueda Y; Hatano E; Kakiuchi N; Takeda H; Goto T; Shimizu T; Yoshida K; Ikura Y; Shiraishi Y; Chiba K; Tanaka H; Miyano S; Uemoto S; Chiba T; Ogawa S; Marusawa H
Int J Cancer; 2016 Dec; 139(11):2512-8. PubMed ID: 27511114
[TBL] [Abstract][Full Text] [Related]
9. TERT Promoter Mutation in Serum Cell-Free DNA Is a Diagnostic Marker of Primary Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease.
Akuta N; Kawamura Y; Kobayashi M; Arase Y; Saitoh S; Fujiyama S; Sezaki H; Hosaka T; Kobayashi M; Suzuki Y; Suzuki F; Ikeda K; Kumada H
Oncology; 2021; 99(2):114-123. PubMed ID: 32998139
[TBL] [Abstract][Full Text] [Related]
10. Rare Pathogenic Variants Predispose to Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease.
Pelusi S; Baselli G; Pietrelli A; Dongiovanni P; Donati B; McCain MV; Meroni M; Fracanzani AL; Romagnoli R; Petta S; Grieco A; Miele L; Soardo G; Bugianesi E; Fargion S; Aghemo A; D'Ambrosio R; Xing C; Romeo S; De Francesco R; Reeves HL; Valenti LVC
Sci Rep; 2019 Mar; 9(1):3682. PubMed ID: 30842500
[TBL] [Abstract][Full Text] [Related]
11. Human telomerase reverse transcriptase messenger RNA (TERT mRNA) as a tumour marker for early detection of hepatocellular carcinoma.
El-Mazny A; Sayed M; Sharaf S
Arab J Gastroenterol; 2014 Jun; 15(2):68-71. PubMed ID: 25097049
[TBL] [Abstract][Full Text] [Related]
12. Comparing clinical presentations, treatments and outcomes of hepatocellular carcinoma due to hepatitis C and non-alcoholic fatty liver disease.
Than NN; Ghazanfar A; Hodson J; Tehami N; Coldham C; Mergental H; Manas D; Shah T; Newsome PN; Reeves H; Shetty S
QJM; 2017 Feb; 110(2):73-81. PubMed ID: 27634970
[TBL] [Abstract][Full Text] [Related]
13. The characteristics and risk factors of hepatocellular carcinoma in nonalcoholic fatty liver disease without cirrhosis.
Tobari M; Hashimoto E; Taniai M; Kodama K; Kogiso T; Tokushige K; Yamamoto M; Takayoshi N; Satoshi K; Tatsuo A
J Gastroenterol Hepatol; 2020 May; 35(5):862-869. PubMed ID: 31597206
[TBL] [Abstract][Full Text] [Related]
14. Risk factors and diagnostic biomarkers for nonalcoholic fatty liver disease-associated hepatocellular carcinoma: Current evidence and future perspectives.
Ueno M; Takeda H; Takai A; Seno H
World J Gastroenterol; 2022 Jul; 28(27):3410-3421. PubMed ID: 36158261
[TBL] [Abstract][Full Text] [Related]
15. MBOAT7 rs641738 variant and hepatocellular carcinoma in non-cirrhotic individuals.
Donati B; Dongiovanni P; Romeo S; Meroni M; McCain M; Miele L; Petta S; Maier S; Rosso C; De Luca L; Vanni E; Grimaudo S; Romagnoli R; Colli F; Ferri F; Mancina RM; Iruzubieta P; Craxi A; Fracanzani AL; Grieco A; Corradini SG; Aghemo A; Colombo M; Soardo G; Bugianesi E; Reeves H; Anstee QM; Fargion S; Valenti L
Sci Rep; 2017 Jul; 7(1):4492. PubMed ID: 28674415
[TBL] [Abstract][Full Text] [Related]
16. Incidence and predictors of hepatocellular carcinoma in NAFLD without diagnosed cirrhosis: a nationwide real-world U.S. study.
Huang DQ; Tran S; Barnett S; Zou B; Yeo YH; Cheung R; Nguyen MH
Hepatol Int; 2024 Apr; 18(2):540-549. PubMed ID: 38079023
[TBL] [Abstract][Full Text] [Related]
17. Incidence of hepatocellular carcinoma in nonalcoholic fatty liver disease without cirrhosis or advanced liver fibrosis.
Behari J; Gougol A; Wang R; Luu HN; Paragomi P; Yu YC; Molinari M; Chopra K; Malik SM; Geller D; Yuan JM
Hepatol Commun; 2023 Jul; 7(7):. PubMed ID: 37395730
[TBL] [Abstract][Full Text] [Related]
18. Cancer Risk in Patients With Biopsy-Confirmed Nonalcoholic Fatty Liver Disease: A Population-Based Cohort Study.
Simon TG; Roelstraete B; Sharma R; Khalili H; Hagström H; Ludvigsson JF
Hepatology; 2021 Nov; 74(5):2410-2423. PubMed ID: 33811766
[TBL] [Abstract][Full Text] [Related]
19. Positive Hepatitis B Core Antibody Is Associated With Cirrhosis and Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease.
Chan TT; Chan WK; Wong GL; Chan AW; Nik Mustapha NR; Chan SL; Chong CC; Mahadeva S; Shu SS; Lai PB; Chan HL; Wong VW
Am J Gastroenterol; 2020 Jun; 115(6):867-875. PubMed ID: 32149781
[TBL] [Abstract][Full Text] [Related]
20. Clinical Patterns and Outcome of Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease.
Ahn SY; Kim SB; Song IH
Can J Gastroenterol Hepatol; 2020; 2020():4873875. PubMed ID: 32566546
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
